Neeraj Agarwal Highlights STELLAR-002 Results in ccRCC at ASCO 2025

Neeraj Agarwal, Postdoctoral fellow at City of Hope, posted on X:

“Congrats Jad Chahoud on the terrific talk About 4515 at ASCO25.

Phase 1b STELLAR-002 study of zanzalintinib + nivo +/- relatlimab in pts with ccRCC.

ORR 63% w/ zanza+nivo (adding relatlimab does not help), key takeaway.”